Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Kymera to ($0.68) (from ($0.74)) and now projects FY2026 EPS of ($2.76), versus the Street consensus full‑year estimate of ($3.35).
• Analyst sentiment is broadly positive — MarketBeat shows a consensus rating of Moderate Buy with a consensus target price of $118.70, and multiple firms (UBS, Citi, Jefferies, RBC) recently issued buy ratings or raised targets.
• Kymera’s Q1 results materially beat expectations, reporting EPS of ($0.71) vs. a consensus of ($0.89) and revenue of $34.37M versus $8.27M, a 55.5% year‑over‑year revenue increase.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report released on Monday, May 4th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.68) for the quarter, up from their prior forecast of ($0.74). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($3.35) per share. HC Wainwright also issued estimates for Kymera Therapeutics' Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.76) EPS, FY2027 earnings at ($3.21) EPS, FY2028 earnings at ($3.30) EPS, FY2029 earnings at ($2.65) EPS and FY2030 earnings at $1.07 EPS.

Several other analysts have also commented on the company. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research report on Monday, March 16th. They issued a "buy" rating and a $110.00 price objective on the stock. Citigroup raised their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. UBS Group lifted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a report on Tuesday, March 3rd. Finally, Stephens boosted their target price on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $118.70.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $82.71 on Wednesday. The company's fifty day moving average price is $84.42 and its 200-day moving average price is $76.61. Kymera Therapeutics has a 1-year low of $28.06 and a 1-year high of $103.00. The firm has a market capitalization of $6.80 billion, a P/E ratio of -23.17 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.82) EPS.

Insiders Place Their Bets

In other news, Director Bruce Booth sold 5,900 shares of the business's stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director directly owned 5,641 shares in the company, valued at $507,464.36. The trade was a 51.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the transaction, the chief executive officer owned 666,195 shares in the company, valued at $54,081,710.10. This trade represents a 4.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 380,734 shares of company stock valued at $32,193,902 in the last three months. 16.01% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP increased its stake in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC lifted its stake in Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after buying an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock worth $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Finally, State Street Corp increased its stake in Kymera Therapeutics by 9.4% during the 4th quarter. State Street Corp now owns 2,209,837 shares of the company's stock worth $171,947,000 after buying an additional 190,383 shares in the last quarter.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.